scholarly journals Low CD34+ Cell Doses Are Associated with Increased Cost and Worse Outcome after Tandem Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Germ Cell Tumors

2018 ◽  
Vol 24 (7) ◽  
pp. 1497-1504 ◽  
Author(s):  
Mustafa A. Hyder ◽  
W. Scott Goebel ◽  
Kirsten D. Ervin ◽  
Jennifer E. Schwartz ◽  
Michael J. Robertson ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Germ Cell Tumors

scholarly journals Melphalan, Etoposide, and Carboplatin Megatherapy with Autologous Stem Cell Transplantation in Children with Relapsing or Therapy-Resistant Extracranial Germ-Cell Tumors—A Retrospective Analysis

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3841
Author(s):  
Marek Ussowicz ◽  
Monika Mielcarek-Siedziuk ◽  
Jakub Musiał ◽  
Mateusz Stachowiak ◽  
Jadwiga Węcławek-Tompol ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Germ Cell Tumors ◽  
High Dose Chemotherapy ◽  
Observation Time ◽  
High Dose ◽  
Line Chemotherapy

Pediatric germ cell tumors (GCTs) are a group of chemosensitive malignancies with a 90% curability rate. We report a series of children with relapsing or therapy-resistant GCT treated with melphalan–etoposide–carboplatin high-dose chemotherapy (HDCT) and autologous stem cell transplantation. This consisted of 18 children, either with GCTs after relapse (nine patients) or with an unsatisfactory response to first-line chemotherapy (nine patients), who underwent HDCT. The HDCT regimens MEC1 (carboplatin 1500 mg/m2, etoposide 1800 mg/m2, and melphalan 140 mg/m2) and MEC2 (carboplatin 800 mg/m2, etoposide 800 mg/m2, and melphalan 140 mg/m2) were each used in nine patients. The median observation time was 81 months, the 5-year overall survival (OS) was 76%, and the event-free survival (EFS) was 70.8%. Non-relapse mortality was 0%, and four patients died after HDCT due to progression of the malignancy. No difference in OS or EFS was noted between the MEC1 and MEC2 protocols. The 5-year OS and 5-year EFS were higher in children treated with autologous stem cell transplantation before the age of four years. The presence of metastatic disease or time of HDCT consolidation during first/subsequent line chemotherapy did not affect patient survival. The melphalan–etoposide–carboplatin protocol is feasible in pediatric GCT, but is associated with potentially life-threatening complications. In conclusion, the use of HDCT must be examined in well-designed clinical trials, and the identification of patients who can benefit from this approach is critical to avoid overtreatment.

Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era

2019 ◽  
Vol 17 (1) ◽  
pp. 58-64.e1 ◽  
Author(s):  
Anis A. Hamid ◽  
Sarah C. Markt ◽  
Cécile Vicier ◽  
Kathleen McDermott ◽  
Paul Richardson ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Germ Cell Tumors ◽  
Modern Era ◽  
Transplantation Outcomes

High-dose chemotherapy and autologous stem cell transplantation in refractory/metastatic nonseminomatous germ cell-tumors: A retrospective study of the Turkish Oncology Association.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15623-e15623
Author(s):  
Mustafa Ozturk ◽  
Fikret Arpaci ◽  
Sukru Ozaydin ◽  
Nuri Karadurmus ◽  
Evren Ozdemir ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Testicular Cancer ◽  
Germ Cell ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Combination Chemotherapy ◽  
Germ Cell Tumors ◽  
High Dose Chemotherapy ◽  
High Dose

e15623 Background: Testicular cancer is a chemosensitive tumor that may be curable even in relapsed disease. Those patients who do not respond to standard combination chemotherapy or relaps may be treated with high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as salvage therapy. Methods: Eighty five patients that received HDC and ASCT between Feb 1993 - Dec 2012 in different university clinics of Turkey were retrospectively reviewed and evaluated. Results: Median age of the patients was 24 (range: 11-54 years) and 63 patients (74,1%) had stage III, 21 (24,7%) had stage II disease at initial diagnosis. The primary tumor location was testis in 71 patients (83,5%), and 14 patients (16,5%) had extragonadal region origin. Evaluation of metastatic focuses before HDC and ASCT was as follows: Liver metastasis (n = 23, 27.05%), lung involvement (n = 23, 27.05%) and multiorgan involvement (n =14, 16.47%) and other metastatic involvements (n=4, 4.7%). ICE (ifosfamide, carboplatin, etoposide) regimen was performed as HDC in all patients. Median follow-up was 59 (range: 8-218) months. Pre-ASCT patients’ condition was complete remission (n=28, 32.9%), partial remission (n=36, 42.4%) and never in CR (n=21, 24.7%) respectively. 32 patients (37.6%) relapsed or progressed within 1 year after HDC and ASCT median relaps was time 3 months (range: 0.3 - 36.13). Transplant related mortality was %3.5 and 3 patients died within the engraftment period after HDC. Five-year overall survival rate was 59.7%. Conclusions: HDC and ASCT is an effective and safe approach for patients with metastatic and refractory germ cell testicular cancer patients that do not respond to standard combination chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document